KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only
about
ALK Signaling and Target Therapy in Anaplastic Large Cell LymphomaThe role of the ALK receptor in cancer biologyTackling ALK in non-small cell lung cancer: the role of novel inhibitorsNon-small cell lung cancer: current treatment and future advancesNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibInhibitors of the anaplastic lymphoma kinaseDifferential methylation analysis for BS-seq data under general experimental design.CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer.Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report.Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularChromogenic in situ hybridisation (CISH) is a powerful method to detect ALK-positive non-small cell lung carcinomas.ALK in lung cancer: past, present, and future.A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung.A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients.Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in TaiwanOverview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondIntegrated analysis of DNA methylation and microRNA regulation of the lung adenocarcinoma transcriptome.Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerClinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement.Genetic and biochemical alterations in non-small cell lung cancer.Biomarkers and targeted systemic therapies in advanced non-small cell lung cancerProspective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncologyTargeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods.Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.Tyrosine kinase gene rearrangements in epithelial malignancies.ALK: a tyrosine kinase target for cancer therapy.Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
P2860
Q21129306-2A6EC244-DE56-486E-A48F-AF67CE01C3C3Q26738384-719519F5-463C-485B-9C68-7107E5B35CCCQ26740329-4595D8EB-91D2-400A-BE69-B97E5B61983DQ26740333-B14D11E1-A130-42D5-A410-0961FAF4651EQ26741814-FFE895E2-FFBF-42C5-9AB0-E2BA31B3C3C4Q26795555-4FAFDA1F-ED19-45F6-A3A8-CD2C7849B29CQ26828860-32B60B4E-5844-43C8-BD11-7056A5C7F168Q27852699-11E71394-424D-48F0-A50A-68143E731B82Q27853072-541264A9-9DC9-4F4F-8644-BA851074EE11Q28267124-0B7C1FFF-4A45-40DD-A360-15711D8F180EQ31040608-36912B38-65E5-48B3-B648-92A3257D4F8EQ33684384-868C2A81-8030-4F0C-8AB4-867354137C0AQ33728943-70CAC148-F880-4C6E-958B-A45A7CF9875FQ33844713-372521B9-89BB-498C-B215-14E884E1F2DDQ34159011-2A535B09-C673-466D-833D-252CA671E770Q34389047-3A7998C0-0787-4035-A9C9-D100EF6EE4BDQ34402260-877A60E9-31C4-4C4A-97B0-8452C17D1B1DQ34686818-DA41E1B7-4EDC-40E8-A32A-8B523232BA13Q34924658-4C21CF18-10DA-493A-9572-7BD7071057C8Q34947842-0ACE1CBE-75D3-4314-9197-E2D1F5BE5B2AQ35256603-90922F8A-3B2C-48B2-BF61-45DECD0E0B63Q35256622-F5432771-9674-4443-90D7-8019781CCDD5Q35805617-5B82C351-75C4-4F19-A1C8-8A56612A919AQ36096398-5E962B2F-F639-48B6-8A50-F2D22BAEA830Q36121158-1851A13E-AFC0-4831-A662-5A8510284BFEQ36184584-7896F1D0-7AA4-4A4A-A030-835F1B63A542Q36260477-D5BBDADA-0E50-48CD-83E3-070DAC2480F7Q36384499-C1DFD9A8-1625-42BA-B194-AD2319F58149Q36405628-1E4552F4-8348-4288-A9F6-05408C125591Q36635602-2DA33D50-6B28-4782-9E3E-7C20402003ABQ36731901-F62D98DB-C3A1-4C46-9828-66FE5C819A50Q36850900-F12CBC76-B2DD-4562-A62A-76268817E704Q36866859-2BB66BCD-7DBA-46D5-8A3C-F6511693AD8EQ36946796-C4150F55-D671-47FD-8EF5-20CD9CED0367Q37392933-F876EF71-11D7-4210-8781-00023437EA35Q37515966-0DFA0484-1262-4B9E-A79A-5DD0B2746774Q37518624-2CC9F572-1F9A-43F7-8FB7-6CB3006A0B17Q37604076-84D8142A-1754-428D-8429-81CFD25C5351Q37631021-EA54D833-2457-462D-97CC-CFF9768A9FEAQ37696243-86368E2F-5324-4318-AD22-1901F4D78FD5
P2860
KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@ast
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@en
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@nl
type
label
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@ast
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@en
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@nl
prefLabel
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@ast
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@en
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@nl
P2093
P2860
P1433
P1476
KLC1-ALK: a novel fusion in lu ...... paraffin-embedded tissue only
@en
P2093
Emiko Sugawara
Hiroyuki Mano
Manabu Soda
Reimi Asaka
Satoko Hatano
Seiji Sakata
Takashi Nakajima
Yuki Togashi
P2860
P304
P356
10.1371/JOURNAL.PONE.0031323
P407
P577
2012-02-08T00:00:00Z